Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

J. Connor Wells

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

J..C. Wells1, C. Ho2, B. Melosky2, J. Laskin3, Y. Wang3, M. Mullin4, S. Sun5

Author affiliations

  • 1 Medical Oncology, BC Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 2 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 3 Medical Oncology, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 4 Respirology, UBC - The University of British Columbia, V5Z 1M9 - Vancouver/CA
  • 5 Division Of Medical Oncology, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1406P

Background

Osimertinib is a standard first line treatment for advanced EGFR mutant lung cancer. While EGFR tyrosine kinase inhibitors are generally well tolerated, side effects, including diarrhea and rash, are common and often require dose modifications. The impact of osimertinib dose modification on survival outcomes is not known.

Methods

Patients with metastatic EGFR mutant lung cancer who received first line osimertinib between 2020 and 2022 were retrospectively identified using pharmacy records in British Columbia, Canada. Patient charts were reviewed to determine the incidence of dose reductions or treatment cessation of osimertinib due to toxicity. The type of toxicity leading to the treatment modification was also recorded. The median time to treatment discontinuation (mTTD) and the median overall survival (mOS) of patients requiring dose modification was compared to those who did not require modification using Kaplan Meier analysis and log rank testing.

Results

The analysis identified 311 patients and with a median follow up time of 26 months. 72 (23%) patients required a dose modification due to toxicity. At time of analysis, 52/72 (72%) of the dose modification group had stopped osimertinib vs 142/239 (60%) in the no modification group. The most frequent toxicities leading to dose reduction or cessation included diarrhea (17), skin toxicity (13), respiratory symptoms (10), anorexia (9), and cardiotoxicity (6). Pneumonitis occurred in 9 patients (3% of the study population). Twenty patients ultimately discontinued osimertinib due to toxicity. The mTTD was shorter in the dose reduction group, 14.3 months (95%CI 11.0-21.3) vs 21.9 months (95%CI 16.9-24.5) in the no reduction group (p=0.042). Second line treatment was received by 19/52 (35%) in the dose modification group and 59/145 (42%) in the no modification group. The mOS of patients requiring dose modifications was 27.6 months (95% CI 21.1-34.1), which was similar to patients not requiring dose modifications, mOS 26.8 months (95% CI 21.9-33.1), p=0.868.

Conclusions

Nearly one quarter of patients treated with osimertinib required a dose reduction or treatment cessation. Despite this, dose modifications did not lead to worse mOS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

C. Ho: Financial Interests, Personal, Speaker, Consultant, Advisor: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Takeda. B. Melosky: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca Canada, Bristol Myers Squibb, Roche, Pfizer, Johnson and Johnson, Novartis, Amgen. J. Laskin: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche Canada, Pfizer, Jazz, AstraZeneca. Y. Wang: Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Merck, AstraZeneca. S. Sun: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.